Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir plus pegylated interferon/ribavirin versus pegylated interferon/ribavirin for acute genotype 1 hepatitis C in HIV-1 coinfected adults
2012-005525-75Phase 3Completed
- Sponsor
- St Stephen's AIDS Trust
- Start
- Apr 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatitis C virus infection and Human immunodeficiency virus infection type 1 comparing Incivo + pegylated interferon + ribavirin with Pegylated interferon + ribavirin (2 arms). Primary endpoint: Sustained virologic response at 24 weeks. Started Apr 2013; status: completed.
02
Drugs
telaprevirpegylated interferon alpharibavirin
03
Conditions
hepatitis C virus infectionHuman immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2012-005525-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005525-75.